Soleno Therapeutics (SLNO)
(Delayed Data from NSDQ)
$42.03 USD
+2.30 (5.79%)
Updated Jul 3, 2024 01:00 PM ET
After-Market: $41.95 -0.08 (-0.19%) 7:58 PM ET
4-Sell of 5 4
D Value C Growth D Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
SLNO 42.03 +2.30(5.79%)
Will SLNO be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for SLNO based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for SLNO
Soleno Therapeutics, Inc. (SLNO) Is a Great Choice for 'Trend' Investors, Here's Why
Here's Why Momentum in Soleno Therapeutics, Inc. (SLNO) Should Keep going
SLNO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Here's What Could Help Soleno Therapeutics, Inc. (SLNO) Maintain Its Recent Price Strength
Biotech Stock Roundup: ICPT Up on Buyout Deal, IMVT & PLRX Gain on Study Data
Soleno (SLNO) Soars as Prader-Willi Syndrome Study Meets Goal
Other News for SLNO
Soleno Therapeutics Announces Submission of New Drug Application to the U.S. FDA for DCCR (Diazoxide Choline) Extended-Release Tablets for the Treatment of Prader-Willi Syndrome
Soleno Therapeutics submits NDA for DCCR extended-release tablets
Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Piper Sandler Sticks to Their Buy Rating for Soleno Therapeutics (SLNO)
Soleno Therapeutics Set to Join Russell 3000® Index